Page 1418 - Hematology_ Basic Principles and Practice ( PDFDrive )

1264 Part VII Hematologic Malignancies

Awan FT, Hillmen P, Hellmann A, et al: A randomized, open-label, multi- Herishanu Y, Pérez-Galán P, Liu D, et al: The lymph node microenvironment
centre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab promotes B-cell receptor signaling, NF-kappaB activation, and tumor
in combination with fludarabine, cyclophosphamide and rituximab versus proliferation in chronic lymphocytic leukemia. Blood 117:563, 2011.
fludarabine, cyclophosphamide and rituximab alone in subjects with Keating MJ, O’Brien S, Albitar M, et al: Early results of a chemoimmu-
relapsed chronic lymphocytic leukaemia. Br J Haematol 167:466–477, notherapy regimen of fludarabine, cyclophosphamide, and rituximab
2014. as initial therapy for chronic lymphocytic leukemia. J Clin Oncol
Badoux XC, Keating MJ, Wang X, et al: Fludarabine, cyclophosphamide, and 23(18):4079–4088, 2005.
rituximab chemoimmunotherapy is highly effective treatment for relapsed Kikushige Y, Ishikawa F, Miyamoto T, et al: Self-renewing hematopoietic stem
patients with CLL. Blood 117:3016, 2011. cell is the primary target in pathogenesis of human chronic lymphocytic
Badoux XC, Keating MJ, Wen S, et al: Lenalidomide as initial therapy of leukemia. Cancer Cell 20:246, 2011.
elderly patients with chronic lymphocytic leukemia. Blood 118:3489, Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study
2011. of bendamustine compared with chlorambucil in previously untreated
Burger JA, Tedeschi A, Barr PM, et al: Ibrutinib as initial therapy for patients patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378, 2009.
with chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437, O’Brien S, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for
2015. elderly patients with chronic lymphocytic leukaemia or small lymphocytic
Byrd JC, Brown JR, O’Brien S, et al: Ibrutinib versus ofatumumab in previ- lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol
ously treated chronic lymphoid leukemia. N Engl J Med 371:213–223, 15:48–58, 2014.
2014. Parikh SA, Strati P, Tsang M, et al: Should IGHV status and FISH testing
Byrd JC, Furman RR, Coutre SE, et al: Three-year follow-up of treatment- be performed in all CLL patients at diagnosis? A systematic review and
naïve and previously treated patients with CLL and SLL receiving single- meta-analysis. Blood 127(14):1752–1760, 2016.
agent ibrutinib. Blood 125:2497–2506, 2015. Puente XS, Pinyol M, Quesada V, et al: Whole-genome sequencing identifies
Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101,
relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42, 2013. 2011.
Chen CI, Bergsagel PL, Paul H, et al: Single-agent lenalidomide in the Robak T, Dmoszynska A, Solal-Céligny P, et al: Rituximab plus fludarabine
treatment of previously untreated chronic lymphocytic leukemia. J Clin and cyclophosphamide prolongs progression-free survival compared with
Oncol 29:1175, 2011. fludarabine and cyclophosphamide alone in previously treated chronic
Crowther-Swanepoel D, Corre T, Lloyd A, et al: Inherited genetic susceptibil- lymphocytic leukemia. J Clin Oncol 28:1756, 2010.
ity to monoclonal B-cell lymphocytosis. Blood 116:5957, 2010. Rogers KA, Ruppert AS, Bingman A, et al: Incidence and description of
Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival autoimmune cytopenias during treatment with ibrutinib for chronic
in chronic lymphocytic leukemia. N Engl J Med 343(26):1910–1916, lymphocytic leukemia. Leukemia 30:346–350, 2016.
2000. Shanafelt TD, Drake MT, Maurer MJ, et al: Vitamin D insufficiency and
Dreger P, Döhner H, Ritgen M, et al: German CLL Study Group: Allogeneic prognosis in chronic lymphocytic leukemia. Blood 117:1492, 2011.
stem cell transplantation provides durable disease control in poor-risk Sorror ML, Storer BE, Sandmaier BM, et al: Five-year follow-up of patients
chronic lymphocytic leukemia: long-term clinical and MRD results of the with advanced chronic lymphocytic leukemia treated with allogeneic
German CLL Study Group CLL3X trial. Blood 116:2438, 2010. hematopoietic cell transplantation after nonmyeloablative conditioning.
Eichhorst BF, Busch R, Stilgenbauer S, et al: German CLL Study Group J Clin Oncol 26:4912, 2008.
(GCLLSG): First-line therapy with fludarabine compared with chloram- Stilgenbauer S, Zenz T, Winkler D, et al: German Chronic Lymphocytic
bucil does not result in a major benefit for elderly patients with advanced Leukemia Study; Subcutaneous alemtuzumab in fludarabine-refractory
chronic lymphocytic leukemia. Blood 114:3382, 2009. chronic lymphocytic leukemia: clinical results and prognostic marker
Eichhorst BF, Fischer K, Fink AM, et al: German CLL Study Group analyses from the CLL2H study of the German Chronic Lymphocytic
(GCLLSG): Limited clinical relevance of imaging techniques in the Leukemia Study Group. J Clin Oncol 27:3994, 2009.
follow-up of patients with advanced chronic lymphocytic leukemia: Tam CS, Keating MJ: Chemoimmunotherapy of chronic lymphocytic
results of a meta-analysis. Blood 117:1817, 2011. leukemia. Nat Rev Clin Oncol 7:521, 2010.
Fabbri M, Bottoni A, Shimizu M, et al: Association of a microRNA/TP53 Tam CS, O’Brien S, Wierda W, et al: Long-term results of the fludarabine,
feedback circuitry with pathogenesis and outcome of B-cell chronic cyclophosphamide, and rituximab regimen as initial therapy of chronic
lymphocytic leukemia. JAMA 305:59, 2011. lymphocytic leukemia. Blood 112:975, 2008.
Fabbri G: Dalla-favera R. The molecular pathogenesis of chronic lymphocytic Wierda WG, Kipps TJ, Mayer J, et al: Hx-CD20-406 Study Investigators:
leukaemia. Nat Rev Cancer 16(3):145–162, 2016. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-
Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749, 2010.
in patients with relapsed and/or refractory chronic lymphocytic leukemia: Wierda WG, O’Brien S, Wang X, et al: Multivariable model for time to first
A multicenter phase II trial of the German Chronic Lymphocytic Leuke- treatment in patients with chronic lymphocytic leukemia. J Clin Oncol
mia Study Group. J Clin Oncol 29:3559, 2011. 29:4088, 2011.
Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil Woyach JA, Ruppert AS, Heerema NA, et al: Chemoimmunotherapy
in patients with CLL and coexisting conditions. N Engl J Med with fludarabine and rituximab produces extended overall survival and
370(12):1101–1110, 2014. progression-free survival in chronic lymphocytic leukemia: long-term
Hallek M, Cheson BD, Catovsky D, et al: International Workshop on follow-up of CALGB study 9712. J Clin Oncol 29:1349, 2011.
Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treat- Woyach JA, Furman RR, Liu TM, et al: Resistance mechanisms for the Bru-
ment of chronic lymphocytic leukemia: a report from the International ton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370:2286–2294,
Workshop on Chronic Lymphocytic Leukemia updating the National 2014.
Cancer Institute-Working Group 1996 guidelines. Blood 111:5446, Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic
2008. lymphocytic leukemia. J Clin Oncol 28:4473, 2010.
Hallek M, Fischer K, Fingerle-Rowson G, et al: International Group of Zenz T, Mertens D, Küppers R, et al: From pathogenesis to treatment of
Investigators; German Chronic Lymphocytic Leukaemia Study Group: chronic lymphocytic leukaemia. Nat Rev Cancer 10:37, 2010.
Addition of rituximab to fludarabine and cyclophosphamide in patients
with chronic lymphocytic leukaemia: a randomised, open-label, phase 3
trial. Lancet 376:1164, 2010.